The Dutch hypothesis, implications for treatment of chronic obstructive pulmonary disease and asthma in a biomarker, monoclonal antibody world. Experience with IgE and omalizumab in a small pulmonary practice

M. L. Zaremba, K. Elliott, A. Redford, S. Ali, N. Shah, S. Reddy (Port Huron, United States Of America)

Source: Annual Congress 2011 - Airways disease comorbidities and general aspects

Session: Airways disease comorbidities and general aspects
Session type: Thematic Poster Session
Number: 4000

Disease area: Airway diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. L. Zaremba, K. Elliott, A. Redford, S. Ali, N. Shah, S. Reddy (Port Huron, United States Of America). The Dutch hypothesis, implications for treatment of chronic obstructive pulmonary disease and asthma in a biomarker, monoclonal antibody world. Experience with IgE and omalizumab in a small pulmonary practice. Eur Respir J 2011; 38: Suppl. 55, 4000

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Validity of serum surfactant protein D as a lung-specific biomarker in monitoring asthma, chronic obstructive pulmonary disease and chronic bronchitis in Lebanese patients: Preliminary results Source: Annual Congress 2012 - Cell biology, blood and sputum biomarkers in airway diseases Year: 2012
Baseline data and responses to oral steroid intervention in asthma and COPD: interim report from the BIOAIR EU study Source: Annual Congress 2007 - Asthma subphenotypes Year: 2007
Similarities and differences between asthma and chronic obstructive pulmonary disease: treatment and early outcomes Source: Eur Respir J 2003; 21: 30S-35S Year: 2003
The influence of inhalation device for bronchodilators on the results of therapy in primary care patients with bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Asthma control or asthma severity Year: 2008
Epidemiological aspects and early detection of chronic obstructive airway diseases in the elderly Source: Eur Respir J 2003; 21: 3S-9S Year: 2003
Is high level of IgE an additional problem in smoking patients with severe and very severe chronic obstructive pulmonary disease (COPD)? Source: Annual Congress 2012 - COPD: epidemiology and varia Year: 2012
Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: 903-908 Year: 2001
The future of disease monitoring and management: the homework for clinical researchers Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not? Year: 2005
Subphenotyping COPD: is it relevant for therapeutic intervention and disease outcome? Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not? Year: 2005
Detection of asthma and chronic obstructive pulmonary disease in primary care Source: Eur Respir J 2003; 21: 16S-22S Year: 2003
Detection of antibody response against influenza vaccine in patients with chronic obstructive pulmonary disease (COPD) by quantitative ELISA and evalution of clinical findings Source: Annual Congress 2009 - Viruses and respiratory infections: prevalence and mechanisms of infection Year: 2009
Drug prescribing and burden of asthma and chronic obstructive pulmonary disease (COPD): a study from Italian general practitioners Source: Eur Respir J 2005; 26: Suppl. 49, 672s Year: 2005
Delivery of asthma and chronic obstructive pulmonary disease (COPD) services in UK primary care: nurses‘ roles and responsibilities Source: Annual Congress 2007 - Nurses' involvement in the follow-up of patients with COPD and lung cancer Year: 2007
Why is it important to consider (sub)phenotypes of asthma and COPD? Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not? Year: 2005
Need for generalized criteria in evaluating the impact of new drugs in clinical trials involving patients suffering from COPD Source: Annual Congress 2006 - Outcomes for COPD pharmacological trials: from lung function to biomarkers Year: 2006
Adherence to national (UK) respiratory guidelines in general practice Source: Annual Congress 2007 - Delivering respiratory care: the challenges for primary care Year: 2007
The role of inflammatory biomarkers and health related quality of life questionnaires in distinction of exacerbation and stable chronic obstructive pulmonary diseases Source: International Congress 2014 – Markers Year: 2014
Are current treatment recommendations suited to elderly patients with asthma or COPD? Source: Eur Respir Mon; 2009: 43: 267–285 Year: 2009
Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019